Factors associated with durable response to infliximab in Crohn's disease 5 years and beyond : a multicenter international cohort

TitreFactors associated with durable response to infliximab in Crohn's disease 5 years and beyond : a multicenter international cohort
Publication TypeJournal Article
Year of Publication2015
AuthorsJuillerat, P, Sokol, H, Froehlich, F, Yajnik, V, Beaugerie, L, Lucci, M, Burnand, B, Macpherson, AJ, Cosnes, J, Korzenik, JR
JournalInflammatory Bowel Diseases
Volume21
Issue1
Pagination60-70
Date Published01/2015
DOI10.1097/MIB.0000000000000225
ISSN1536-4844
Mots-clésAdolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Case-Control Studies, Child, Crohn Disease, Female, Follow-Up Studies, Humans, Immunosuppressive Agents, International Agencies, Male, Middle Aged, Prospective Studies, Registries, Remission Induction, Retrospective Studies, Survival Rate, Time Factors, Treatment Outcome, Young Adult
Abstract

BACKGROUND: Infliximab (IFX) has been used for over a decade worldwide. Less is known about the natural history of IFX use beyond a few years and which patients are more likely to sustain benefits.

METHODS: Patients with Crohn's disease (CD) exposed to IFX from Massachusetts General Hospital, Boston, Saint-Antoine Hospital, Paris, and the Swiss IBD Cohort Study were identified through retrospective and prospective data collection, complemented by chart abstraction of electronic medical records. We compared long-term users of IFX (>5 yr of treatment, long-term users of infliximab [LTUI]), with non-LTUI patients to identify prognostic factors.

RESULTS: We pooled data on 1014 patients with CD from 3 different databases, of whom 250 were defined as LTUI. The comparison group comprised 290 patients with CD who discontinued IFX: 48 primary nonresponses, 95 loss of responses, and 147 adverse events. Factors associated with LTUI were colonic involvements and an earlier age at the start of IFX. The prevalence of active smokers and obese patients differed markedly, but inversely, between American and European centers but did not impact outcome. The discontinuation rate was stable around 3% to 6%, each year from years 3 to 10.

CONCLUSIONS: Young age at start of IFX and colonic CD are factors associated with a beneficial long-term use of IFX. After 5 years of IFX, there is still a 3% to 5% discontinuation rate annually. Several factors associated with a good initial response such as nonsmoker and shorter disease duration at IFX initiation do not seem associated with a longer term response.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/25517594?dopt=Abstract

WOS ID (UT)

000348906500012

Alternate JournalInflamm. Bowel Dis.
Citation Key / SERVAL IDserval:BIB_B5FE837EFF22
Peer reviewRefereed
PubMed ID25517594

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | dess.info@unisante.ch

Go to top